CGCaroline V. Greaves

Caroline V. Greaves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline V. Greaves has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Benson Complex Figure Test detects deficits in visuoconstruction and visual memory in symptomatic familial frontotemporal dementia: A GENFI study

    by Lize C. Jiskoot, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Caroline V. Greaves, Martina Bocchetta, Jackie M. Poos, Harro Seelaar, Lucia A.A. Giannini, John C. van Swieten, et al.


  • Developing a consensus protocol for genetic testing in frontotemporal dementia

    by Caroline V Greaves, Nayana Lahiri, Jonathan D Rohrer, The Genetic Frontotemporal Dementia Initiative (GENFI) and UK Predictive Testing Consortium

    Background: Frontotemporal dementia (FTD) is genetic in around 30% of people. The aim of the study was to develop a consensus protocol for genetic testing in FTD.Methods: A Delphi methodology was used to achieve consensus recommendations from an international consortium of FTD and neurogenetics specialists. Participants were presented with a number of scenarios involving an asymptomatic individual from a family with a history of FTD but no known genetic mutation, who is requesting predictive testing. Consensus was defined as a recommendation being selected by >80% of respondents.Results: 1) If an affected relative is alive and able to consent for diagnostic testing, a sample should be taken to ascertain whether there is a genetic form of FTD in the family before the asymptomatic individual can pursue predictive testing. 2) In the case where the affected relative is alive but unable to consent to diagnostic testing, experts decided that a blood or saliva sample could be taken if possible, and with the family’s agreement diagnostic testing could be performed to ascertain whether a mutation is present prior to predictive testing. 3) When there is no living affected relative but a sample of DNA or tissue has been stored, experts agreed that diagnostic testing should be performed on the sample, independent of family history, prior to offering predictive testing. 4) In the case where there is no living relative and no stored DNA or tissue but there is known pathology in a deceased family member that is pathognomonic for a specific genetic form of FTD, the consensus was to perform predictive testing based on that pathology. 5) Where there is no stored sample available, experts were in agreement that predictive testing should not be offered.Conclusions: This revised protocol will provide guidance to clinicians for FTD‐specific genetic testing.

  • Exploring the experiences of living at risk of familial frontotemporal dementia

    by Caroline V Greaves, Joshua Stott, Jonathan D Rohrer

    Background: Frontotemporal dementia is the second most common form of dementia in those under 65 years of age and is found to be genetic in around a third of cases. Familial FTD has an autosomal dominant pattern of inheritance meaning that the offspring of a mutation carrier has a 50% chance of carrying the mutation themselves. For those at risk of FTD, there are a number of issues that can cause distress including the high penetrance of the most common FTD‐causing genes, heterogeneity of symptoms and unpredictable age of symptom onset. Despite this, there have been no studies looking at the experiences of this group, particularly those who do not pursue predictive testing.Method: Sixteen qualitative interviews were analysed using an inductive approach to thematic analysis. Participants were asked about their experience finding out about their risk, how they felt throughout different parts of their journey, their experience of genetic testing if this was performed, as well as the support they had or feel they would have benefited from.Result: Key themes identified included: 1) Depression, uncertainty and survivor guilt – the ups and downs of living at‐risk, 2) Worries about the wider family, 3) Lack of support ‐ “You need people who really understand”, 4) Coping mechanisms ‐ Living like a gene carrier and 5) Seeing at risk status as a positive thing. Almost all participants expressed a need for tailored psychological support facilitated by “someone who understands” the unique issues they face.Conclusion: Living at risk of familial FTD is a psychologically challenging experience, independent of the challenges presented by predictive testing. Those who choose not to undergo predictive testing may also, at times, require specific support. Future research should explore tailored support strategies to assist people in coping with these challenges.


  • Open Access

    Segmentation of medial temporal subregions reveals early right-sided involvement in semantic variant PPA

    by Martina Bocchetta, Juan Eugenio Iglesias, Lucy L. Russell, Caroline V. Greaves, Charles R. Marshall, Marzia A. Scelsi, David M. Cash, Sebastien Ourselin, Jason D. Warren, Jonathan D. Rohrer

    Semantic variant of primary progressive aphasia (svPPA) is a subtype of frontotemporal dementia characterized by asymmetric temporal atrophy. We investigated the pattern of medial temporal lobe atrophy in 24 svPPA patients compared to 72 controls using novel approaches to segment the hippocampal and amygdalar subregions on MRIs. Based on semantic knowledge scores, we split the svPPA group into 3 subgroups of early, middle and late disease stage. Early stage: all left amygdalar and hippocampal subregions (except the tail) were affected in svPPA (21–35% smaller than controls), together with the following amygdalar nuclei in the right hemisphere: lateral, accessory basal and superficial (15–23%). On the right, only the temporal pole was affected among the cortical regions. Middle stage: the left hippocampal tail became affected (28%), together with the other amygdalar nuclei (22–26%), and CA4 (15%) on the right, with orbitofrontal cortex and subcortical structures involvement on the left, and more posterior temporal lobe on the right. Late stage: the remaining right hippocampal regions (except the tail) (19–24%) became affected, with more posterior left cortical and right extra-temporal anterior cortical involvement. With advanced subregions segmentation, it is possible to detect early involvement of the right medial temporal lobe in svPPA that is not detectable by measuring the amygdala or hippocampus as a whole.